搜尋結果
2022年3月30日 · Background. The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19...
2022年12月14日 · To the Editor: Reis et al. (May 5 issue)1 present the results of the TOGETHER platform trial, a large trial of ivermectin in outpatients with Covid-19. The relative risk of hospitalization or...
- Recommendation
- Rationale
- References
The Panel recommends against the use of ivermectin for the treatment of COVID-19 (AIIa).
The Panel’s recommendation is primarily informed by adequately powered, randomized trials of ivermectin that reported clinical outcomes. Studies that randomized participants to receive ivermectin or a matched placebo had the greatest impact on the Panel’s recommendation.6-13
Trials have failed to find a clinical benefit of using ivermectin to treat COVID-19 in outpatients. In TOGETHER, an adaptive platform trial conducted in Brazil, there was no apparent difference between the ivermectin and placebo arms for the primary outcome of risk of emergency department visits or hospitalization (14.7% vs. 16.4%).14 In addition, there was no statistically significant difference between the ivermectin and placebo arms in mortality (3.1% vs. 3.5%). In COVID-OUT, a randomized factorial trial, the use of ivermectin did not reduce the occurrence of a composite outcome of emergency department visits, hospitalization, or death when compared with a matched control (5.7% vs. 4.1%).6
Omura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30(9):445-455. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25130507.
Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15(3):325-332. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26954318.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32251768.
Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg. 2020;102(6):1156-1157. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32314704.
2021年8月17日 · 伊維菌素 (Ivermectin) 對 COVID-19 感染症是否有效？. 關鍵資訊. 我們沒有發現任何證據表示使用伊維菌素能有效治療或預防 COVID-19 感染症。. 此佐證資料仍持續更新中，但證據仍然有限。. 目前仍有 31 項針對伊維菌素的研究在進行中，我們將在其得出結論後更新本 ...
2022年8月17日 · Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes, Journal of Infection, 88, 4, (106130...
2021年6月15日 週二 上午11:07 ·7 分鐘. 近來《美國治療學期刊（American Journal of Therapeutics）》一篇評論指出，口服抗寄生蟲藥物「伊維菌素（ Ivermectin）」有機會預防新冠病毒感染，且能縮短新冠病人的恢復期、降低死亡率。. 這般訊息令人眼睛為之一亮，但證據 ...
2021年6月21日 · For trials of COVID-19 treatment, 16 evaluated ivermectin among participants with mild to moderate COVID-19 only; 6 trials included patients with severe COVID-19. Most compared ivermectin with placebo or no ivermectin; 3 trials included an active comparator 1
